J M Sivik1, J Davidson2, C M Hale3, J J Drabick2, G Talamo2. 1. Department of Pharmacy, Penn State Health-M.S. Hershey Medical Center, Hershey, PA, USA. jsivik@pennstatehealth.psu.edu. 2. Department of Medicine, Hematology/Oncology Division, Penn State College of Medicine, Hershey, PA, USA. 3. Department of Pharmacy, Penn State Health-M.S. Hershey Medical Center, Hershey, PA, USA.
Abstract
BACKGROUND: The most commonly used antibacterial prophylaxis during autologous stem cell transplants (ASCT) for multiple myeloma (MM) involves a fluoroquinolone, such as ciprofloxacin or levofloxacin. We assessed the impact of adding doxycycline to ciprofloxacin as routine antibacterial prophylaxis in these patients. METHODS: We retrospectively reviewed electronic medical records and our ASCT database to analyze rates and types of bacterial infections in MM patients who underwent ASCT in our institution. RESULTS: Among 419 patients, 118 received ciprofloxacin alone (cipro group), and 301 ciprofloxacin and doxycycline (cipro-doxy group). Neutropenic fever (NF) developed in 63 (53%) and 108 (36%) patients of the cipro and cipro-doxy groups, respectively (p = 0.010). The number of documented bacteremic episodes was 13 (11%) and 14 (4.7%) in the two groups, respectively (p = 0.017). Antimicrobial resistance and Clostridium difficile infections were uncommon. Transplant-related mortality was 1% in both groups. CONCLUSIONS: The addition of doxycycline to standard prophylaxis with ciprofloxacin seems to reduce the number of NF episodes and documented bacterial infections in patients with MM undergoing ASCT, without increasing rate of serious complications.
BACKGROUND: The most commonly used antibacterial prophylaxis during autologous stem cell transplants (ASCT) for multiple myeloma (MM) involves a fluoroquinolone, such as ciprofloxacin or levofloxacin. We assessed the impact of adding doxycycline to ciprofloxacin as routine antibacterial prophylaxis in these patients. METHODS: We retrospectively reviewed electronic medical records and our ASCT database to analyze rates and types of bacterial infections in MMpatients who underwent ASCT in our institution. RESULTS: Among 419 patients, 118 received ciprofloxacin alone (cipro group), and 301 ciprofloxacin and doxycycline (cipro-doxy group). Neutropenic fever (NF) developed in 63 (53%) and 108 (36%) patients of the cipro and cipro-doxy groups, respectively (p = 0.010). The number of documented bacteremic episodes was 13 (11%) and 14 (4.7%) in the two groups, respectively (p = 0.017). Antimicrobial resistance and Clostridium difficileinfections were uncommon. Transplant-related mortality was 1% in both groups. CONCLUSIONS: The addition of doxycycline to standard prophylaxis with ciprofloxacin seems to reduce the number of NF episodes and documented bacterial infections in patients with MM undergoing ASCT, without increasing rate of serious complications.
Authors: S R Parmar; R Bookout; J F Shapiro; R Tombleson; J Perkins; J Kim; B Yue; M Tomblyn; M Alsina; T Nishihori Journal: Bone Marrow Transplant Date: 2014-03-24 Impact factor: 5.483
Authors: U Narayanasami; R Kanteti; J Morelli; A Klekar; A Al-Olama; C Keating; C O'Connor; E Berkman; J K Erban; K A Sprague; K B Miller; D P Schenkein Journal: Blood Date: 2001-10-01 Impact factor: 22.113
Authors: Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard Journal: Clin Infect Dis Date: 2011-02-15 Impact factor: 9.079
Authors: R St Bernard; L Chodirker; E Masih-Khan; H Jiang; N Franke; V Kukreti; R Tiedemann; S Trudel; D Reece; C I Chen Journal: Bone Marrow Transplant Date: 2014-10-06 Impact factor: 5.483